Abstract
Radiation nephropathy and other normal tissue radiation injuries can be successfully mitigated, and also treated, by antagonists of the renin-angiotensin system (RAS). This implies a mechanistic role for that system in radiation nephropathy, yet no evidence exists to date of activation of the RAS by irradiation. RAS antagonists, including angiotensin converting enzyme inhibitors and angiotensin receptor blockers, are the standard of care in the treatment of subjects with other chronic progressive kidney diseases, in which they exert benefit by reducing both glomerular and tubulo-interstitial injury. These drugs are likely to act in a similar way to mitigate radiation nephropathy.
Keywords: Radiation injuries, radiation nephropathy, renin-angiotensin system, angiotensins, captopril, mesangiolysis, Radiation, nephropathy, angiotensin, (TBI), (BMT), Mitigation, (ACE), (BUN), (DMFs), losartan, (HSCT), RAS, (NO), (AcSDKP), bradykinin, (AVE0991), DNA, NADPH oxidase, glomerular
Current Drug Targets
Title: Mitigation of Radiation Injuries via Suppression of the Renin-Angiotensin System: Emphasis on Radiation Nephropathy
Volume: 11 Issue: 11
Author(s): E. P. Cohen, B. L. Fish and J. E. Moulder
Affiliation:
Keywords: Radiation injuries, radiation nephropathy, renin-angiotensin system, angiotensins, captopril, mesangiolysis, Radiation, nephropathy, angiotensin, (TBI), (BMT), Mitigation, (ACE), (BUN), (DMFs), losartan, (HSCT), RAS, (NO), (AcSDKP), bradykinin, (AVE0991), DNA, NADPH oxidase, glomerular
Abstract: Radiation nephropathy and other normal tissue radiation injuries can be successfully mitigated, and also treated, by antagonists of the renin-angiotensin system (RAS). This implies a mechanistic role for that system in radiation nephropathy, yet no evidence exists to date of activation of the RAS by irradiation. RAS antagonists, including angiotensin converting enzyme inhibitors and angiotensin receptor blockers, are the standard of care in the treatment of subjects with other chronic progressive kidney diseases, in which they exert benefit by reducing both glomerular and tubulo-interstitial injury. These drugs are likely to act in a similar way to mitigate radiation nephropathy.
Export Options
About this article
Cite this article as:
P. Cohen E., L. Fish B. and E. Moulder J., Mitigation of Radiation Injuries via Suppression of the Renin-Angiotensin System: Emphasis on Radiation Nephropathy, Current Drug Targets 2010; 11 (11) . https://dx.doi.org/10.2174/1389450111009011423
DOI https://dx.doi.org/10.2174/1389450111009011423 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multimodality Imaging in Cardiac Sarcoidosis: Is There a Winner?
Current Cardiology Reviews The Role of Matrix Gla Protein (MGP) in Vascular Calcification
Current Medicinal Chemistry Outcomes of Perilla Seed Oil as an Additional Neuroprotective Therapy in Patients with Mild to Moderate Dementia: A Randomized Control Trial
Current Alzheimer Research The Stable Isotope Use in the Exploration of Bioavailability and Metabolism of Magnesium
Current Nutrition & Food Science New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury
Current Drug Targets Inflammatory Cardiovascular Risk Markers in Obstructive Sleep Apnoea Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacogenomics and Sepsis-Induced Renal Failure: Effects of β 2-Adrenoceptor Function on the Course of Sepsis
Current Pharmacogenomics and Personalized Medicine Molecular and Vascular Targets in the Pathogenesis and Management of the Hypertension Associated with Preeclampsia
Cardiovascular & Hematological Agents in Medicinal Chemistry Non-Invasive Assessment of Non-Alcoholic Fatty Liver Disease: Ultrasound and Transient Elastography
Reviews on Recent Clinical Trials Dermatologic Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Antioxidant Capacity, Phytochemical Analysis and Identification of Active Compounds in Anchomanes difformis
The Natural Products Journal Visceral and Subcutaneous Adiposity: Are Both Potential Therapeutic Targets for Tackling the Metabolic Syndrome?
Current Pharmaceutical Design Secondary Prevention of Ischemic Stroke
Current Drug Targets Protocatechuic Acid Alkyl Esters: Hydrophobicity As a Determinant Factor for Inhibition of NADPH Oxidase
Current Medicinal Chemistry Lead Encephalopathy Due to Traditional Medicines
Current Drug Safety Cardiotonic Steroids: Novel Mechanisms of Na+ i-Mediated and - Independent Signaling Involved in the Regulation of Gene Expression, Proliferation and Cell Death
Current Hypertension Reviews Sodium Ion Transporters as New Therapeutic Targets in Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Early Brain Injury or Vasospasm? An Overview of Common Mechanisms
Current Drug Targets Cerebrovascular Profile Assessment in Parkinson's Disease Patients
CNS & Neurological Disorders - Drug Targets Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar
Current Vascular Pharmacology